Recital 2, Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for i…

In forcesince 27 Apr 2000

In order to implement Article 3 of Regulation (EC) No 141/2000, additional details on the factors that should be considered when establishing prevalence, likely return on investment and the satisfactory nature of alternative methods of diagnosis, prevention and treatment may be helpful for sponsors and the Committee for Orphan Medicinal Products.